As our knowledge of Thyroid Eye Disease (TED) pathogenesis has advanced in recent years, with the delineation of the inflammatory pathways activated in the orbit as well as the critical role of insulin-growth factor I on the orbital fibroblast of TED patients, we have had a significant expansion of therapeutic options, as well as a continued interest in the development of novel therapies for this debilitating disease. The goal of Innovate TED will be to educate attendees with the most up-to-date developments in the field, encourage discussions across our disciplines, promote exchange of knowledge, enhance collaboration, celebrate the multidisciplinary care of TED patients, and stimulate further innovation in TED therapies.
At the conclusion of this activity, participants should be able to:
Target course participants include ophthalmologists, oculoplastic surgeons, endocrinologists, optometrists, trainees in these fields, primary care providers, patient advocates, and advanced practice providers involved in the care of patients with thyroid eye disease (TED). This inclusivity shows a commitment to spreading knowledge and awareness across all stakeholders involved in the care of patients with TED.